Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

NCT03224767 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

BRAF V600E Mutation Present
Papillary Craniopharyngioma

Interventions

DRUG: Vemurafenib
DRUG: Cobimetinib
OTHER: Laboratory Biomarker Analysis
OTHER: Quality-of-Life Assessment

Sponsor

Alliance for Clinical Trials in Oncology

Collaborators

[object Object]